Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|February 16, 2016
Bohle dry granulator BRC
L.B. Bohle rounds off the comprehensive offer of granulation solutions with the dry granulator series BRC25 and 100. In the dry granulator powders are processed into fluid granules. Please send in the text for your profile. This should be no more than 200 words. Please also supply a 30-word summary of your profile, 1 x image, 1 x logo, contact details including email and web address.
Advertisement
Easy handling, continuous production and a small footprint are the typical features with which Bohle now covers the comprehensive portfolio of wet and dry granulation.
L.B. Bohle rounds off the comprehensive offer of granulation solutions with the dry granulator series BRC 25 and 100.
In the dry granulator powders are processed into fluid granules. The objective in the pharmaceutical industry is to process a granule with defined density or porosity for immediate tableting thereafter.
Easy control, easy cleaning and fewer edges, screws and angles - these are the essential features of the BRC.
Especially the control of the pressing force via standard hydraulic systems constitutes a great problem, when the process is to comply with "hygienic design". The electro-mechanical batch can solve this problem.
With the Bohle BRC, frequent axis adjustment as with traditional roller compactors is a thing of the past. The axes are mechanically stable so that elastic deformation is prevented. This eliminates the need for complete axes control. Moreover, the BRC is low maintenance. When cleaning is required, only four screws must be removed. Bohle engineers also reduced the footprint. Further advantages of the BRC are the identical roller geometry and control in both machines allowing easy scale-up.
Contact Details :
L.B. Bohle Maschinen + Verfahren GmbH
Website:
E-mail:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement